Back AIDS 2010

AIDS 2010

AIDS 2010: HPV-associated Cancer among HIV Positive Men and Women in the Combination ART Era

Precancerous anal cell changes and infection with high-risk human papillomavirus (HPV) types remain common among men with HIV despite effective antiretroviral therapy (ART) that suppresses viral load and restores CD4 cell levels, according to a study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. A related study found that invasive cervical cancer -- also caused by HPV -- was associated with lower CD4 cell counts among HIV positive women in the large NA-ACCORD cohort.

alt

Read more:

Long-term Non-progression of HIV Disease without Antiretroviral Treatment Is Uncommon

Less than 1% of people infected with HIV for 15 years did not experience disease progression in the absence of antiretroviral therapy (ART), according to findings from the CASCADE cohort reported at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. Even at 5 years after seroconversion, all but 10% progressed to the point of requiring treatment, and only 0.25% were considered HIV controllers with sustained undetectable viral load.

alt

Read more:

AIDS 2010: HIV Treatment Advances Have Not Decreased Mortality among Disadvantaged Groups in San Francisco

While effective combination antiretroviral therapy (ART) has reduced overall morbidity and mortality due to HIV/AIDS, everyone has not benefited equally. According to a San Francisco study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna, members of socially disadvantaged groups -- including injection drug users, heavy alcohol users, individuals with mental health problems, people of color, women, and transgender people -- were less likely to achieve undetectable HIV viral load and their all-cause mortality increased slightly rather than falling over time.

alt

Read more:

Switching from Efavirenz to Etravirine Reduces Central Nervous System Side Effects

HIV patients who started antiretroviral treatment using the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (Intelence) experienced fewer neuropsychiatric side effects such as abnormal dreams and anxiety compared with those taking efavirenz (Sustiva), and those who switched from efavirenz to etravirine saw an improvement in such symptoms, according to 2 studies presented last month at the XVIII International AIDS Conference (AIDS 2010) in Vienna.

alt

Read more: